Compare Stocks: PCSA, UPC, LPCN, and ZIVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPCN Lipocine	$2.18 -1.8%	$2.20	$1.81 ▼ $12.37	$18.30M	0.47	25,426 shs	50,450 shs
PCSA Heatwurx	$1.95 +3.5%	$2.22	$1.67 ▼ $14.24	$5.20M	0.96	30,497 shs	15,606 shs
UPC Universe Pharmaceuticals	$4.46 -7.3%	$4.85	$2.00 ▼ $17.96	$24.17M	1.58	327,431 shs	59,806 shs
ZIVO ZIVO Bioscience	$4.10	$4.18	$1.11 ▼ $17.50	$17.28M	0.16	2,964 shs	23 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPCN Lipocine	-1.80%	-7.63%	+3.32%	-6.84%	-26.25%
PCSA Heatwurx	+3.46%	-9.95%	-19.96%	-9.53%	-61.18%
UPC Universe Pharmaceuticals	-7.28%	+6.19%	-21.06%	+53.26%	+14.36%
ZIVO ZIVO Bioscience	0.00%	+31.73%	-4.45%	+11.11%	-69.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPCN Lipocine	$2.18 -1.8%	$2.20	$1.81 ▼ $12.37	$18.30M	0.47	25,426 shs	50,450 shs
PCSA Heatwurx	$1.95 +3.5%	$2.22	$1.67 ▼ $14.24	$5.20M	0.96	30,497 shs	15,606 shs
UPC Universe Pharmaceuticals	$4.46 -7.3%	$4.85	$2.00 ▼ $17.96	$24.17M	1.58	327,431 shs	59,806 shs
ZIVO ZIVO Bioscience	$4.10	$4.18	$1.11 ▼ $17.50	$17.28M	0.16	2,964 shs	23 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPCN Lipocine	-1.80%	-7.63%	+3.32%	-6.84%	-26.25%
PCSA Heatwurx	+3.46%	-9.95%	-19.96%	-9.53%	-61.18%
UPC Universe Pharmaceuticals	-7.28%	+6.19%	-21.06%	+53.26%	+14.36%
ZIVO ZIVO Bioscience	0.00%	+31.73%	-4.45%	+11.11%	-69.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LPCN Lipocine	1.50	Reduce	$15.00	588.07% Upside
PCSA Heatwurx	1.00	Sell	N/A	N/A
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PCSA, UPC, LPCN, and ZIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	PCSA Heatwurx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LPCN Lipocine	$1.57M	11.45	N/A	N/A	$2.61 per share	0.84
PCSA Heatwurx	N/A	N/A	N/A	N/A	$2.46 per share	N/A
UPC Universe Pharmaceuticals	$17.86M	1.25	N/A	N/A	$99.64 per share	0.04
ZIVO ZIVO Bioscience	$15.85K	1,090.32	N/A	N/A	($0.81) per share	-5.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
PCSA Heatwurx	-$13.56M	-$4.23	N/A	N/A	N/A	N/A	-394.25%	-244.46%	10/29/2026 (Estimated)
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$1.40	N/A	N/A	N/A	N/A	N/A	-2,240.92%	12/2/2026 (Estimated)

Latest PCSA, UPC, LPCN, and ZIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	PCSA Heatwurx	-$1.00	-$1.19	-$0.19	-$1.19	N/A	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LPCN Lipocine	N/A	11.48	11.48
PCSA Heatwurx	N/A	0.87	0.87
UPC Universe Pharmaceuticals	0.04	4.05	3.90
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LPCN Lipocine	9.11%
PCSA Heatwurx	91.93%
UPC Universe Pharmaceuticals	0.18%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
LPCN Lipocine	4.69%
PCSA Heatwurx	3.50%
UPC Universe Pharmaceuticals	57.38%
ZIVO ZIVO Bioscience	21.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LPCN Lipocine	10	8.24 million	7.86 million	No Data
PCSA Heatwurx	20	2.77 million	2.67 million	Not Optionable
UPC Universe Pharmaceuticals	220	5.02 million	2.14 million	N/A
ZIVO ZIVO Bioscience	10	4.22 million	2.91 million	Not Optionable

PCSA, UPC, LPCN, and ZIVO Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened

September 11, 2026 | americanbankingnews.com

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

May 12, 2026 | businesswire.com

Zivo Bioscience Inc. Wt

April 11, 2026 | barrons.com

ZIVO Bioscience Provides Special Letter to Shareholders

March 27, 2026 | businesswire.com

Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)

December 15, 2025 | theglobeandmail.com

ZIVO Bioscience releases letter to shareholders

September 14, 2025 | wattagnet.comW

ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

September 10, 2025 | businesswire.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PCSA, UPC, LPCN, and ZIVO Company Descriptions

Lipocine NASDAQ:LPCN

$2.18 -0.04 (-1.80%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.21 +0.03 (+1.28%)

As of 09/15/2026 04:15 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Heatwurx NASDAQ:PCSA

$1.94 +0.07 (+3.46%)

Closing price 09/15/2026 03:50 PM Eastern

Extended Trading

$2.00 +0.05 (+2.83%)

As of 09/15/2026 07:30 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Universe Pharmaceuticals NASDAQ:UPC

$4.46 -0.35 (-7.28%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$4.47 +0.01 (+0.34%)

As of 09/15/2026 07:55 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

ZIVO Bioscience NASDAQ:ZIVO

$4.10 0.00 (0.00%)

As of 09/14/2026

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSA, UPC, LPCN, and ZIVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSA, UPC, LPCN, and ZIVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSA, UPC, LPCN, and ZIVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PCSA, UPC, LPCN, and ZIVO Company Descriptions

Lipocine NASDAQ:LPCN

Heatwurx NASDAQ:PCSA

Universe Pharmaceuticals NASDAQ:UPC

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSA, UPC, LPCN, and ZIVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSA, UPC, LPCN, and ZIVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSA, UPC, LPCN, and ZIVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PCSA, UPC, LPCN, and ZIVO Company Descriptions

Lipocine NASDAQ:LPCN

Heatwurx NASDAQ:PCSA

Universe Pharmaceuticals NASDAQ:UPC

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools